research The Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
Antihistamines may help with hair regrowth in alopecia areata, but dupilumab's effects are mixed.
Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Psoriatic Alopecia and Paradoxical Psoriasis Induced by Adalimumab Successfully Treated with Certolizumab: Clinical, Trichoscopic, and in vivo Reflectance Confocal Microscopy Features
Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
research Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
Tofacitinib may be safe and effective for treating certain skin conditions in children.
research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Ruxolitinib cream may help treat severe hair loss in children.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
Ixekizumab is safe for long-term use with low rates of major heart-related events.
research Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
research Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
Apremilast improved symptoms in patients with severe skin conditions.
research 490 Samcyprone (diphenylcyclopropenone ointment) for the treatment of common warts
Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
research 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
research Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-κB inhibition
A new cream, DHMEQ, reduces allergic skin inflammation effectively.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research Potencial de nanopartículas poliméricas de Delonix contendo isotretinoína para o tratamento da acne
Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
research Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata
Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
research Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
research Alopecia Areata Associated with Dupilumab: A Case Report and Literature Review
Dupilumab may cause hair loss, so patients should be monitored.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials
Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
research Predstanormix Duo – a new domestic combination drug for the treatment of lower urinary tract dysfunction symptoms associated with BPH.
Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.